亨迪药业：盐酸埃克替尼获上市申请批准

Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of hydrochloride erlotinib, a targeted drug for treating non-small cell lung cancer [1] Group 1: Company Information - Hendi Pharmaceutical is the developer of hydrochloride erlotinib, an EGFR tyrosine kinase inhibitor [1] - The drug is primarily used for treating locally advanced or metastatic non-small cell lung cancer with sensitive mutations in the EGFR gene [1] Group 2: Industry Context - Hydrochloride erlotinib can also be used for treating advanced non-small cell lung cancer patients who have failed previous chemotherapy [1]